Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.45 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28745316 | 0.87 | PTPN1 (0.48) | PTPN1HDAC2HDAC1HDAC3 | |
| SCHEMBL10024278 | 0.81 | KDM4E (0.54) | PTPN1ACLYKDM4EDHODHHDAC2 | |
| SCHEMBL1546629 | 0.80 | KDM4E (0.52) | PTPN1ACLYKDM4EHDAC2HDAC1 | |
| SCHEMBL2770912 | 0.80 | DCLRE1B (0.59) | ACLYKDM4EDCLRE1ADCLRE1B | |
| SCHEMBL22126665 | 0.80 | HNF4A (0.59) | PTPN1ACLYKDM4EDHODHFTO | |
| SCHEMBL14137893 | 0.80 | ERN1 (0.58) | PTPN1HDAC2HDAC1HDAC3ERN1 | |
| SCHEMBL10024261 | 0.78 | PTPN1 (0.55) | PTPN1ACLYKDM4EDHODHHDAC2 | |
| SCHEMBL21857924 | 0.78 | KCNH2 (0.62) | PTPN1ACLYHDAC2HDAC1HDAC3 | |
| SCHEMBL4652841 | 0.78 | PTPN1 (0.51) | PTPN1ACLYKDM4EDHODHHDAC2 | |
| SCHEMBL27816589 | 0.77 | ALDH1A1 (0.49) | PTPN1KDM4EHDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| EP-2573069-A2 | Inhibitors of histone deacetylase and prodrugs thereof | MethylGene Inc. (CA) | 2013-03-27 | — | — | EP | disclosed |
| US-RE43343-E1 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| EP-1233958-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2011-06-29 | — | — | EP | disclosed |
| EP-1973872-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | Methylgene, Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008074132-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-RE39850-E1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2007-09-18 | — | — | US | disclosed |
| EP-1748046-A2 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2007-01-31 | — | — | EP | disclosed |
| US-6541661-B1 | For treating cell proliferative diseases and conditions | METHYLGENE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| EP-1233958-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001038322-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | PTPN1 1882/4885ACLY 1127/4885KDM4E 71/4885 |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | PTPN1 1882/4885ACLY 1127/4885KDM4E 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.